Drugs & Targets Syapse, FDA form research collaboration on the regulatory use of real-world evidence September 06, 2019Vol.45 No.33
Drugs & Targets Calquence granted Breakthrough Therapy designation for CLL September 06, 2019Vol.45 No.33
Drugs & Targets European Commission approves Empliciti + pomalidomide and dexamethasone for multiple myeloma September 06, 2019Vol.45 No.33
Drugs & Targets European Commission approves Imbruvica for expanded use in two indications September 06, 2019Vol.45 No.33
Drugs & Targets FDA Grants XTANDI application Priority Review for metastatic hormone-sensitive prostate cancer September 06, 2019Vol.45 No.33
Drugs & Targets DARZALEX approved for frontline multiple myeloma in Japan September 06, 2019Vol.45 No.33
Drugs & Targets FDA draft guidance encourages inclusion of male patients in breast cancer clinical trials September 06, 2019Vol.45 No.33
Drugs & Targets FDA approves darolutamide for non-metastatic castration-resistant prostate cancer August 02, 2019Vol.45 No.31
Drugs & Targets FDA grants breakthrough designation for NKTR-214 in combination with nivolumab for melanoma August 02, 2019Vol.45 No.31
Drugs & Targets EMA adopts positive opinion for Keytruda + Inlyta as first-line for RCC August 02, 2019Vol.45 No.31
